{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:22:46Z","timestamp":1793283766044,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"\n Importance<\/jats:title>\n Prior authorization (PA) is widely used by insurers to control health care costs and promote high-value care, but it can create significant barriers to accessing medications. This is particularly concerning in neurology, where timely treatment is critical to avoid disease progression and optimize patient outcomes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the consequences, barriers, and facilitators of PA policies affecting access to pharmacologic treatment in 6 common neurologic conditions\u2014Alzheimer disease, Parkinson disease, multiple sclerosis, migraine, cerebrovascular disease, and epilepsy\u2014with focus on impacts on patients, clinicians, and administrators.<\/jats:p>\n <\/jats:sec>\n \n Evidence Review<\/jats:title>\n \n The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (\n PRISMA<\/jats:ext-link>\n ) reporting guidelines for scoping reviews were followed, and the study protocol was registered on Open Science Framework. MEDLINE and Embase were searched up to November 1, 2024, using Ovid for studies that assessed the role of PA as a primary or secondary outcome for the 6 included neurologic conditions, or for neurology broadly if strongly applicable to the study aim, after the signage of the Affordable Care Act in March 2010. Abstract screening and full-text review were done in duplicate. Key information was charted in extraction, including study characteristics, demographics, methods, results, and implications for relevant stakeholders. The results were aggregated and thematically analyzed.\n <\/jats:p>\n <\/jats:sec>\n \n Findings<\/jats:title>\n A total of 364 studies were identified using our search strategy on Ovid, 278 records were screened, and 20 studies were included in this review. The most frequently identified consequences for patients were delays in care (60%) and increase in disease activity (25%). The most frequently identified consequence for clinicians (35%) and administrators (15%) was time burden. The most common facilitators were the use of clinical pharmacists or technicians (20%) and health system specialty pharmacies (15%).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n According to the results of this scoping review, PA can contribute to significant access barriers for people with neurological conditions and is associated with burden for all stakeholders involved. Reforms to PA can work towards more equitable access to medications for patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2025.4560","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:01:13Z","timestamp":1765209673000},"page":"181","source":"Crossref","is-referenced-by-count":9,"title":["Barriers and Consequences of Prior Authorization for Neurologic Medications"],"prefix":"10.1001","volume":"83","author":[{"given":"Evelyn","family":"Gotlieb","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Department of Neurology, Weill Cornell Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bamby","family":"Joseph","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Blank","sequence":"additional","affiliation":[{"name":"Division of Health Outcomes and Knowledge Translation Research, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Institute for Healthcare Delivery, Department of Population Health and Policy, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Jett\u00e9","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"15","key":"nrv250002r1","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1212\/WNL.0b013e3181d8fff4","article-title":"Impact of insurance status on migraine care in the United States: a population-based study.","volume":"74","author":"Wilper","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"nrv250002r2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1526-4610.2012.02265.x","article-title":"Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features.","volume":"53","author":"Lipton","year":"2013","journal-title":"Headache"},{"issue":"21","key":"nrv250002r3","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1212\/WNL.0000000000001608","article-title":"The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?","volume":"84","author":"Hartung","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"nrv250002r4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3111\/13696998.2013.778268","article-title":"The cost burden of multiple sclerosis in the United States: a systematic review of the literature.","volume":"16","author":"Adelman","year":"2013","journal-title":"J Med Econ"},{"issue":"7","key":"nrv250002r5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11910-021-01118-x","article-title":"Economics of multiple sclerosis disease-modifying therapies in the USA.","volume":"21","author":"Hartung","year":"2021","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"nrv250002r6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/01.NT.0001005528.27176.a7","article-title":"Neurology drugs are getting better\u2014and more expensive\u2014with more prior authorization hassles.","volume":"24","author":"Burling","year":"2024","journal-title":"Neurol Today"},{"issue":"1","key":"nrv250002r8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1377\/hlthaff.23.1.113","article-title":"Medicare drug coverage and moral hazard.","volume":"23","author":"Pauly","year":"2004","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"nrv250002r9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S0167-6296(00)00033-3","article-title":"Moral hazard in physician prescription behavior.","volume":"19","author":"Lundin","year":"2000","journal-title":"J Health Econ"},{"key":"nrv250002r10","article-title":"Rationing medicine through bureaucracy: authorization restrictions in Medicare.","author":"Brot-Goldberg","year":"2023","journal-title":"National Bureau of Economic Research"},{"issue":"1","key":"nrv250002r12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1001\/jamaneurol.2023.4324","article-title":"Streamlining prior authorization to improve care.","volume":"81","author":"Busis","year":"2024","journal-title":"JAMA Neurol"},{"key":"nrv250002r13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pediatrneurol.2018.03.006","article-title":"Impact of prior authorization of antiepileptic drugs in children with epilepsy.","volume":"83","author":"Wirrell","year":"2018","journal-title":"Pediatr Neurol"},{"issue":"2","key":"nrv250002r15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40120-020-00195-3","article-title":"Impact of formulary restrictions on antiepileptic drug dispensation outcomes.","volume":"9","author":"Mehta","year":"2020","journal-title":"Neurol Ther"},{"issue":"1","key":"nrv250002r16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.NT.0000817608.36002.47","article-title":"Can legislation save the day for challenges related to prior authorization?","volume":"22","author":"Butcher","year":"2022","journal-title":"Neurol Today"},{"issue":"7","key":"nrv250002r17","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1212\/WNL.0000000000206485","article-title":"A headache for a headache: variability in prior authorizations as a bottleneck for patient access to CGRP-modulating medications to treat migraine (P8-12.010).","volume":"102","author":"Yan","year":"2024","journal-title":"Neurology"},{"issue":"3","key":"nrv250002r18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1017\/S1744133121000153","article-title":"Do patients benefit from legislation regulating step therapy?","volume":"17","author":"Tharp","year":"2022","journal-title":"Health Econ Policy Law"},{"issue":"7","key":"nrv250002r20","first-page":"562","article-title":"Drug plan design incentives among Medicare prescription drug plans.","volume":"20","author":"Huskamp","year":"2014","journal-title":"Am J Manag Care"},{"issue":"5","key":"nrv250002r21","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1002\/alz.13778","article-title":"Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome.","volume":"20","author":"Hillerstrom","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"6","key":"nrv250002r22","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.japh.2022.07.006","article-title":"Specialty pharmacy integration and the role of an advanced certified pharmacy technician in prescription cannabidiol access.","volume":"62","author":"Owens","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"nrv250002r23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.18553\/jmcp.2013.19.1.18","article-title":"Dalfampridine prior authorization program: a cohort study.","volume":"19","author":"Gleason","year":"2013","journal-title":"J Manag Care Pharm"},{"issue":"2","key":"nrv250002r24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/CPJ.0000000000000208","article-title":"Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients.","volume":"6","author":"Bourdette","year":"2016","journal-title":"Neurol Clin Pract"},{"issue":"10","key":"nrv250002r25","doi-asserted-by":"publisher","DOI":"10.2196\/11168","article-title":"The impact of disease-modifying therapy access barriers on people with multiple sclerosis: mixed-methods study.","volume":"20","author":"Simacek","year":"2018","journal-title":"J Med Internet Res"},{"issue":"2","key":"nrv250002r26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1377\/hlthaff.2018.05357","article-title":"Trends in coverage for disease-modifying therapies for multiple sclerosis in Medicare Part D.","volume":"38","author":"Hartung","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"nrv250002r27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.18553\/jmcp.2021.27.2.256","article-title":"Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy.","volume":"27","author":"Peter","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"nrv250002r28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1212\/CPJ.0000000000001118","article-title":"Association between pharmacy benefit restrictions and disease-modifying therapy use in the Medicare Part D program.","volume":"12","author":"Hartung","year":"2022","journal-title":"Neurol Clin Pract"},{"issue":"1","key":"nrv250002r29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7224\/1537-2073.2022-069","article-title":"The impact of insurance restrictions in newly diagnosed individuals with multiple sclerosis.","volume":"26","author":"Mizell","year":"2024","journal-title":"Int J MS Care"},{"issue":"Q3","key":"nrv250002r30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7224\/1537-2073.2023-069","article-title":"Evaluation of a quality measure for multiple sclerosis care: disease-modifying therapy initiation at the University of North Carolina\u2019s outpatient neurology clinic.","volume":"26","author":"Clayton","year":"2024","journal-title":"Int J MS Care"},{"issue":"6","key":"nrv250002r31","first-page":"e175","article-title":"Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.","volume":"24","author":"Stuart","year":"2018","journal-title":"Am J Manag Care"},{"issue":"8","key":"nrv250002r32","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.14181","article-title":"Everything old is new again.","volume":"61","author":"Freitag","year":"2021","journal-title":"Headache"},{"issue":"9","key":"nrv250002r33","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1111\/head.14172","article-title":"Headache infusion centers: a survey on treatments provided, infusion center operations, and barriers to developing new infusion centers.","volume":"61","author":"Strauss","year":"2021","journal-title":"Headache"},{"issue":"4","key":"nrv250002r34","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.37765\/ajmc.2023.89352","article-title":"Prior authorization requirements for calcitonin gene-related peptide antagonists.","volume":"29","author":"Musial","year":"2023","journal-title":"Am J Manag Care"},{"issue":"2","key":"nrv250002r35","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200256","article-title":"Gold carding policies: reducing the barriers between payers and providers.","volume":"14","author":"Nair","year":"2024","journal-title":"Neurol Clin Pract"},{"issue":"3","key":"nrv250002r36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.9740\/mhc.2021.05.187","article-title":"Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access.","volume":"11","author":"Livezey","year":"2021","journal-title":"Ment Health Clin"},{"key":"nrv250002r37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pediatrneurol.2018.03.006","article-title":"Impact of prior authorization of antiepileptic drugs in children with epilepsy.","volume":"83","author":"Wirrell","year":"2018","journal-title":"Pediatr Neurol"},{"issue":"18","key":"nrv250002r38","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1212\/WNL.98.18_supplement.3422","article-title":"Generic substitution of antiseizure medications: is it time for narrow therapeutic index classification?(S24. 006).","volume":"98","author":"Elmer","year":"2022","journal-title":"Neurology"},{"issue":"7","key":"nrv250002r39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1212\/01.wnl.0000319958.37502.8e","article-title":"Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.","volume":"71","author":"Berg","year":"2008","journal-title":"Neurology"},{"issue":"22 Pt 2","key":"nrv250002r40","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1212\/01.wnl.0000313154.55518.25","article-title":"Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.","volume":"70","author":"LeLorier","year":"2008","journal-title":"Neurology"},{"key":"nrv250002r41","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.2147\/DDDT.S106802","article-title":"Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod.","volume":"10","author":"Correale","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"nrv250002r42","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1377\/hlthaff.2021.00036","article-title":"Quantifying the economic burden of drug utilization management on payers, manufacturers, physicians, and patients.","volume":"40","author":"Howell","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"nrv250002r43","first-page":"38","article-title":"Step therapy.","volume":"73","author":"Hoffman","year":"2018","journal-title":"Food Drug Law J"},{"issue":"8","key":"nrv250002r44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/jama.2019.21428","article-title":"Refocusing medication prior authorization on its intended purpose.","volume":"323","author":"Resneck","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"nrv250002r45","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2024.13383","article-title":"Medicare Advantage has become notorious for prior authorization-CMS and lawmakers are taking action.","volume":"332","author":"Cahan","year":"2024","journal-title":"JAMA"},{"key":"nrv250002r7","first-page":"319","volume-title":"Trends in Antiseizure Medication Use: Implications for Practice and Clinical Care","author":"Bensken","year":"2022"},{"key":"nrv250002r11","unstructured":"Grimm? CA. High rates of prior authorization denials by some plans and limited state oversight raise concerns about access to care in Medicaid managed care. US Department of Health and Human Services. Accessed September 22, 2023. https:\/\/oig.hhs.gov\/documents\/evaluation\/3157\/OEI-09-19-00350-Complete%20Report.pdf"},{"key":"nrv250002r14","unstructured":"2024 AMA prior authorization physician survey. American Medical Association. Accessed October 1, 2025. https:\/\/www.ama-assn.org\/system\/files\/prior-authorization-survey.pdf"},{"key":"nrv250002r19","unstructured":"PRISMA-scoping reviews. Accessed January 2, 2025. https:\/\/www.prisma-statement.org\/scoping"},{"key":"nrv250002r46","unstructured":"Rosenbluth? T. In constant battle with insurers, doctors reach for a cudgel: A.I. The New York Times. Accessed October 1, 2025. https:\/\/www.nytimes.com\/2024\/07\/10\/health\/doctors-insurers-artificial-intelligence.html"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2842313\/jamaneurology_gotlieb_2025_rv_250002_1770244417.85969.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:00:26Z","timestamp":1770652826000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2842313"}},"subtitle":["A Scoping Review"],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2025.4560","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}